LUDOVICA MARANDO to Humans
This is a "connection" page, showing publications LUDOVICA MARANDO has written about Humans.
Connection Strength
0.104
-
Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations. Haematologica. 2025 Jan 01; 110(1):22-36.
Score: 0.026
-
Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. Curr Oncol Rep. 2020 06 01; 22(6):61.
Score: 0.019
-
Absence of PNH-clones in DDX41mutant-GPS aids in their distinction from acquired BM failure syndromes. Leuk Res. 2024 Oct; 145:107561.
Score: 0.006
-
Prevalence and significance of DDX41 gene variants in the general population. Blood. 2023 10 05; 142(14):1185-1192.
Score: 0.006
-
Multiparameter prediction of myeloid neoplasia risk. Nat Genet. 2023 09; 55(9):1523-1530.
Score: 0.006
-
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2023 02 16; 29(4):711-722.
Score: 0.006
-
Institutionalising forensic sciences and medicine in centres for newly arrived unaccompanied minors: A case study from Milano. J Forensic Leg Med. 2022 01; 85:102297.
Score: 0.005
-
Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Nat Genet. 2021 10; 53(10):1443-1455.
Score: 0.005
-
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metab. 2020 11 03; 32(5):829-843.e9.
Score: 0.005
-
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J Exp Med. 2019 04 01; 216(4):966-981.
Score: 0.004
-
Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood. 2018 04 12; 131(15):1639-1653.
Score: 0.004
-
From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging. Br J Haematol. 2012 Aug; 158(3):415-8.
Score: 0.003
-
Paroxysmal nocturnal hemoglobinuria after autologous stem cell transplantation: extinction of the clone during treatment with eculizumab - pathophysiological implications of a unique clinical case. Acta Haematol. 2011; 126(2):103-9.
Score: 0.003
-
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009 Apr 23; 113(17):4094-100.
Score: 0.002
-
Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood. 2008 Jul 15; 112(2):449-51.
Score: 0.002